Introduction
Exercise is one of the most common triggers of bronchospasm in those who have chronic asthma. Symptoms alone are inadequate to make a diagnosis of exerciseinduced bronchospasm (EIB); however, there is no accepted gold standard test available. It is increasingly apparent that there is heterogeneity in the inflammatory response associated with EIB that further underscores the need for clarity in terminology, diagnostic testing, and phenotype of the study populations. Each of these can impact on present and future therapies for this significant healthcare problem.
Epidemiology
It is unclear if EIB in those with and without chronic asthma results from the same mechanism. Therefore, it has been proposed that they be labeled differently to reflect the presence or absence of chronic asthma. Weiler et al.
[1 ] led a recent workshop that defined exercise-induced asthma as exercise-induced symptoms and chronic asthma. They defined EIB as bronchospasm triggered by exercise or chronic asthma or both. Irrespective of the terminology, the key point is to be certain the population being studied is explicitly defined not only in terms of underlying chronic asthma but also other key clinical phenotypic features (i.e. atopy), and so on.
Recent data have again confirmed the prevalence of EIB in competitive athletes is increased compared with the general population [2, 3 ]. In one study utilizing eucapnic voluntary hyperventilation (EVH) testing [3 ] , 39% of a cohort of college athletes was found to have EIB. In addition, Knopfli et al.
[2] studied members of the Swiss Triathlon Team over 2 years, and using mathematical modeling concluded these athletes developed EIB quickly, a rate of increase 195-286 times that of the normal rate for development of asthma.
Of concern are the recent reports of objectively documented EIB without reported symptoms of bronchospasm, similar to 'poor perceivers' with chronic asthma [ ]. As many of these mediators involve the airway epithelium, it has been proposed that in a subpopulation of people, EIB may result from airway epithelial injury [12 ] . It certainly seems plausible that airway injury may be a significant event for EIB in select individuals. However, the issue of heterogeneity of EIB is indeed acknowledged by these same authors, as in addition to epithelial-based inflammation, they have previously proposed a variety of inflammatory mediators to be central to the pathogenesis of EIB as well [14] . This heterogeneity in the observed inflammatory response correlated with EIB may be related to variance in the phenotype of participants studied (i.e. chronic asthma, EIB alone, atopy, etc.) [14, 15] .
Recent appreciation for the effects of physical activity on immune function provides additional avenues of thought regarding the role of inflammation in EIB [16 ] . It is clear that chronic physical activity can influence the immune system and likely the subsequent physiologic response to stressors such as exercise. Shaaban et al. [17 ] reported an inverse relationship between exercise and bronchial hyperresponsiveness in 5518 adults, suggesting a correlation between physical activity and the development of asthma and/or EIB. This observation is similar to previous studies in humans [18] [19] [20] and is consistent with recent studies in a mouse model of asthma. Vieira et al. [21 ] demonstrated that chronic aerobic exercise resulted in a decrease in airway inflammation and airway remodeling in an ovalbumin (OVA) model. Pastva et al. [22] had previously demonstrated similar 'anti-inflammatory' effects of chronic aerobic exercise in OVA-sensitized mice and had postulated the effects resulted from decreased activation of NF-kB. However, these data on potentially beneficial 'anti-inflammatory' effects of chronic physical activity are in stark contrast to a large body of literature documenting an increase in the prevalence of EIB among elite and competitive athletes [1 ,23] . Some potential explanations for this apparent paradox of the effect of exercise on lung inflammation have been put forth. Cooper et al. [16 ] proposes that alterations in gene expression in leukocytes in response to exercise may help explain these seemingly contradictory findings. They postulate that chronic exercise could be deleterious if induced genetic changes have made an individual's leukocytes more responsive or 'primed' for an exuberant response to acute bouts of exercise. There are some parallels between this suggestion and Anderson's concept of EIB resulting from repetitive airway injury, though Cooper's concepts might suggest the injury is more systemic and global then just to the airway epithelium.
Thus, despite considerable progress in defining the inflammatory response correlating with EIB, its exact mechanism remains unclear. Recent work has highlighted a heterogeneity in inflammation associated with EIB similar to what is now appreciated in chronic asthma [4 ] . Future studies will require close attention to the phenotype of research participants studied and should attempt to integrate changes in systemic inflammation with those found in the airway. It is likely that other systemic effects of exercise such as lactic acidosis, hypoxemia, and hormonal changes may also influence the production and effects of various inflammatory mediators. In addition, environmental and dietary factors may further influence an individual's response to both chronic and acute exercise [24, 25] . Just as in chronic asthma, it is unlikely one unifying mechanism will be found for EIB that appears to be the end result of various individualized pathways.
Diagnosis
Symptoms alone are inadequate to diagnose EIB, lacking both sensitivity and specificity [1 ,3 ,26] . Accurate diagnosis requires objective testing. Methacholine challenge, field-based or laboratory-based exercise challenge, EVH testing, and mannitol inhalation have all been used to document EIB. In 2007, the variable testing methodology was again demonstrated as Vilozni et al. [27 ] used a freerunning test to evaluate EIB in children 3-6 years of age; Parsons et al. [3 ] used EVH testing in a study of collegiate athletes; and Stensrud et al. [28] studied 24 elite skiers utilizing both methacholine challenge and field-exercise testing. In the Stensrud's study [28] , 37.5% of the skiers had EIB based on methacholine challenge testing but only 8.3% of the same 24 skiers had EIB through field-exercise testing, which exemplifies the discrepancies in reported prevalence rates of EIB based on which objective test is used.
With the lack of a consensus gold standard, the 'best' test to document EIB depends on the population being evaluated and the resources available to the healthcare provider. The gold standard may eventually become a combination of objective lung function testing and analysis of biomarkers such as exhaled nitric oxide (eNO) or exhaled breath condensate. Nishio et al. [29 ] studied the use of eNO and pulmonary function testing to evaluate EIB in 20 asthmatic children and found this to be a valuable diagnostic combination. Hopefully, future trials with larger numbers of participants will shed more light on the diagnostic utility of this and similar approaches.
Treatment
Prophylactic treatment with short-acting bronchodilators prior to exercise remains first-line therapy for EIB [1 ,4 ] . Clinical trials of montelukast in the treatment of EIB continue to produce variable results [30, 31, 32 ]. Philip et al. [32 ] reported that montelukast provided significant protection against EIB in 47 asthmatics (ages 15-44 years) with an onset of action within 2 h. Raissy et al. [30] compared albuterol with montelukast for treating EIB in 11 asthmatic children and found both treatments were superior to placebo, but albuterol was significantly more effective then montelukast. Stelmach et al. [31] showed treatment combinations including montelukast were more effective than those without it. Montelukast appears to be effective in a subset of people with EIB; however, it is difficult to predict who will respond. Thus, it is likely best suited as an adjunctive agent for patients that are not fully controlled with shortacting bronchodilators.
Mickelborough [33
] confirmed a common clinical recommendation demonstrating the combination of a vigorous warm-up with bronchodilators prior to exercise resulted in substantial bronchodilation and conferred a greater protective effect against EIB than either intervention alone. The effect of diet on EIB remains an open question, with another small trial suggesting some effect, in this case an increase in vitamin C intake correlated with a decrease in EIB and select urinary inflammatory markers [34] . Environmental factors, including diet, likely do influence both the development of EIB and its response to various agents. Such factors should be considered in prescribing a treatment plan for an individual with EIB.
Pharmacogenetic studies are ongoing, with Kim et al. [35 ] reporting that a thromboxane A2 receptor (TBXA2R) gene polymorphism may be predictive of a response to leukotriene receptor antagonists in Korean asthmatic children with EIB but that a similar response was not related to leukotriene C4 synthase (LTC4S) and cysteinyl leukotriene receptor 1 (CysLTR1) genes [36] .
Conclusion
There has been much progress in defining EIB clinically and mechanistically. Recent data have only highlighted the ongoing knowledge gaps, and future studies should focus on more precise phenotyping of participants and include more global measures of inflammation in order to develop more effective therapies.
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